Volume 66, Issue 5, Pages (November 2014)

Slides:

Advertisements

Similar presentations

The PSA Era is not Over for Prostate Cancer

Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis Maria I. Carlo, Darren R.

Volume 58, Issue 1, Pages (July 2010)

Volume 63, Issue 2, Pages (February 2013)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 60, Issue 1, Pages (July 2011)

Volume 59, Issue 3, Pages (March 2011)

Volume 199, Issue 2, Pages (February 2018)

Volume 74, Issue 1, Pages (July 2018)

Volume 72, Issue 5, Pages (November 2017)

Volume 51, Issue 1, Pages (January 2007)

Volume 53, Issue 5, Pages (May 2008)

Let the Games Begin (with EAU Approval)

Volume 68, Issue 1, Pages (July 2015)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 50, Issue 5, Pages (November 2006)

John P. Mulhall, Francesco Montorsi European Urology

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 52, Issue 1, Pages (July 2007)

Volume 63, Issue 2, Pages (February 2013)

Volume 66, Issue 2, Pages (August 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 61, Issue 5, Pages (May 2012)

Volume 52, Issue 5, Pages (November 2007)

A Systematic Review of Graft Augmentation Urethroplasty Techniques for the Treatment of Anterior Urethral Strictures Altaf Mangera, Jacob M. Patterson,

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 3, Pages (September 2016)

Volume 65, Issue 4, Pages (April 2014)

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 64, Issue 4, Pages (October 2013)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 60, Issue 5, Pages (November 2011)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Yuanshan Cui, Yong Zhang European Urology

Volume 50, Issue 3, Pages (September 2006)

Volume 61, Issue 6, Pages (June 2012)

Volume 65, Issue 2, Pages (February 2014)

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 6, Pages (December 2011)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Leonard S. Marks, Jiaoti Huang European Urology

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

The Lethal Clone in Prostate Cancer: Redefining the Index

Volume 63, Issue 6, Pages (June 2013)

The Economic Costs of Overactive Bladder in Germany

Volume 53, Issue 1, Pages (January 2008)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 50, Issue 2, Pages (August 2006)

Volume 74, Issue 5, Pages (November 2018)

Volume 72, Issue 5, Pages (November 2017)

Sergio Bracarda European Urology Supplements

European Urology is “Your” Journal

Epidemiology of Renal Cell Carcinoma

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Annika Berntsen, Poul F. Geertsen, Inge Marie Svane European Urology

Joaquim Bellmunt European Urology Supplements

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Jan Roigas European Urology Supplements

Volume 163, Issue 4, (November 2015)

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 66, Issue 5, Pages 874-880 (November 2014) Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma Jose A. Karam, Catherine E. Devine, Diana L. Urbauer, Marisa Lozano, Tapati Maity, Kamran Ahrar, Pheroze Tamboli, Nizar M. Tannir, Christopher G. Wood European Urology Volume 66, Issue 5, Pages 874-880 (November 2014) DOI: 10.1016/j.eururo.2014.01.035 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Consolidated Standards of Reporting Trials diagram. European Urology 2014 66, 874-880DOI: (10.1016/j.eururo.2014.01.035) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Tumor diameter in centimeters, at 7 wk and 12 wk of treatment. Orange indicates partial response, and blue indicates stable disease per Response Evaluation Criteria in Solid Tumors. European Urology 2014 66, 874-880DOI: (10.1016/j.eururo.2014.01.035) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 3 Waterfall plot of tumor response in percentages at 12 wk of treatment. Orange indicates partial response, and blue indicates stable disease per Response Evaluation Criteria in Solid Tumors. European Urology 2014 66, 874-880DOI: (10.1016/j.eururo.2014.01.035) Copyright © 2014 European Association of Urology Terms and Conditions